Joint Clinical Assessment is central to the success of the European Union Health Technology Assessment (EU HTA) Regulation but there are challenges ahead for the oncology, rare disease and advanced therapy medicinal product sectors.

These challenges were discussed by Lumanity at a health economics and outcomes research (HEOR) theater presentation at ISPOR Europe 2022 and form the basis of this whitepaper. Here we consider how product manufacturers can face these challenges positively. 

Complete the form to download the whitepaper.

More from Lumanity on the EU HTA Regulation

Want to find out more about the EU HTA Regulation and how it will affect pharmaceutical companies bringing new products to market in Europe? Head over to Lumanity’s dedicated webpage where you can find all our updates on the Regulation so far, as well as key contacts and details of our training program.

Click here

Download the White Paper

"*" indicates required fields

Sign me up to receive regular insights from Lumanity
By selecting this box, I consent to receive Lumanity marketing communications by email.
This field is for validation purposes and should be left unchanged.